Medical Advocates
HIV Infection/Disease
  Pre-Exposure Prophylaxis Drugs
General Reports
 Adherence
 Resistance
Cabotegravir (GSK-1263744)
Maraviroc
Nevirapine
Rilpivirine
 Tenofovir
 Tenofovir/Emtricitabine
HIV PreP Main Page Main New/Newsworthy Home Page

Last Update:  February 27, 2018
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
     
    Journal Papers, Abstracts, and Commentaries 
 
 

Willingness to Take PrEP for HIV Prevention: The Combined Effects of Race/Ethnicity and Provider Trust.
Braksmajer A, Fedor TM, Chen SR, et al
AIDS Educ Prev. 2018 Feb;30(1):
 Abstract

Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073).
Zhang Y, Clarke W, Marzinke MA,  et al
Antimicrob Agents Chemother. 2017 Apr 24.
 Abstract

Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.
Mullins TL, Zimet G, Lally M, Kahn JA.
AIDS Patient Care STDS. 2016 Jul;30(7):339-48.
Abstract

Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.
Amico KR, Stirratt MJ.
Clin Infect Dis. 2014 Jul 1;59 Suppl 1:S55-60
 Abstract

Study product adherence measurement in the iPrEx placebo-controlled trial: Concordance with drug detection.
Amico KR, Marcus JL, McMahan V,  et al
J Acquir Immune Defic Syndr. 2014 May
Abstract
Antiretrovirals for HIV prevention: when should they be recommended?
Kiselinova M, De Spiegelaere W, Verhofstede C,  et al
 Expert Rev Anti Infect Ther. 2014 Apr;12(4):431-45.
 Abstract

Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence.
Blumenthal J, Haubrich R.
Expert Opin Pharmacother. 2013 Jun 26
 Abstract

Next-generation oral preexposure prophylaxis: beyond tenofovir.
Abraham BK, Gulick R.
Curr Opin HIV AIDS. 2012 nIV1
 Abstract

The clinical pharmacology of antiretrovirals for HIV prevention.
Hendrix CW.
Curr Opin HIV AIDS. 2012 Sep 7.
 Abstract

  

    Videos

 
Pre-Exposure Prophylaxis for HIV Prevention: State of the Art, and Looking to the Future
 
Adherence
     
       Journal Papers, Abstracts, and Commentaries 
    Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.
Gengiah TN, Moosa A, Naidoo A, Mansoor LE.
Int J Clin Pharm. 2014 Feb;36(1):70-85
 Abstract
.
Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy
to effectiveness.
Amico KR.
Curr Opin HIV AIDS. 2012 Sep .
 Abstract
 
State of Science of Adherence in Pre-Exposure Prophylaxis and Microbicide Trials.
Muchomba FM, Gearing RE, Simoni JM, El-Bassel N.
J Acquir Immune Defic Syndr. 2012 Aug 28.
Abstract
Resistance
     

 Journal Papers, Abstracts, and Commentaries 
 

  HIV-1 Drug Resistance in the iPrEx Pre-Exposure Prophylaxis Trial.
Liegler T, Abdel-Mohsen M, Bentley LG,  et al
J Infect Dis. 2014 Apr 16. 
Abstract
Maraviroc
     
     Journal Papers, Abstracts, and Commentaries 
 
  PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, et al
J Infect Dis. 2016 Nov 2.
 Abstract

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Fox J, Tiraboschi JM, Herrera C, et al
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):252-257.
 Abstract

Maraviroc and reverse transcriptase inhibitors combinations as potential pre-exposure prophylaxis candidates.
Herrera C, Armanasco N, García-Pérez J, et al  
AIDS. 2016 Feb 5.
Abstract
Nevirapine
     

     Journal Papers, Abstracts, and Commentaries 
 

  A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission
in uninfected subjects at high risk.
 Jackson JB, Barnett S, Piwowar-Manning E, et al.
AIDS 2003 Mar 7;17(4):547-53
 Abstract
 
Rilpivirine
     

 Journal Papers, Abstracts, and Commentaries 
 

  A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV negative volunteers for pre-exposure prophylaxis (PrEP).
 Jackson AG, Else LJ, Mesquita PM,  et al
Clin Pharmacol Ther. 2014 May 26
 Abstract
Tenofovir
     

      Journal Papers, Abstracts, and Commentaries 

 
FULL-TEXT ARTICLE
 A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
 Cressey TR, Siriprakaisil O, Klinbuayaem V, et al 
BMC Infect Dis. 2017 Jul 14;17(1):496
 Paper

FULL-TEXT ARTICLE
 Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
MacQueen KM, Dlamini S, Perry B, et al
 AIDS Behav. 2016 Nov;20(11):2682-2691.
 Paper

Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
Musinguzi N, Muwonge T, Thomas K, et al
AIDS Behav. 2016 Nov;20(11):2639-2643.
 Abstract

Renal Function and Tenofovir Disoproxil Fumarate for PrEP: How safe is safe enough?
Krakower DS, Mayer KH.  
J Infect Dis. 2016 Apr 27.
 Abstract

Elevations in Serum Creatinine with Tenofovir-Based HIV Pre-exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Yacoub R, Nadkarni GN, Weikum D, et al
J Acquir Immune Defic Syndr. 2015 Nov 30.
 Abstract

Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson KA, Baeten JM, Mugo NR
Curr Opin HIV AIDS. 2015 Sep 28.
 Abstract

FULL-TEXT ARTICLE
A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I, Cranston RD, Duffill K,  et al
PLoS One. 2015 May 5;10(5):e0125363.
 Paper

Mucosal effects of tenofovir 1% gel.(Downlink full-text article)
Hladik F, Burgener A, Ballweber L,  et al
Elife. 2015 Feb 3;4.
 Abstract

FULL-TEXT ARTICLE
 Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM, Ramjee G, Richardson BA,  et al 
N Engl J Med. 2015 Feb 5;372(6):509-18.
Paper

Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis.
Lehman DA, Baeten JM, McCoy CO,  et al  
J Infect Dis. 2015 Jan 13. pii: jiu677.
 Abstract

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM, Donnell D, Mugo NR, et al
Lancet Infect Dis. 2014 Oct 8
 Abstract

FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis.
Corneli AL, Deese J, Wang M,  et al
 J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-331.
 Abstract

Daily Oral Tenofovir and Emtricitabine-Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1-Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial.
Celum C, Morrow RA, Donnell D,  et al
Ann Intern Med. 2014 Jul 1;161(1):11-19.
 Abstract

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention.
Donnell D, Baeten JM, Bumpus NN, et al
J Acquir Immune Defic Syndr. 2014 Apr 29.
Abstract

Antiviral Activity of Genital Tract Secretions following Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1.
Herold BC, Dezzutti CS, Richardson BA,  et al
J Acquir Immune Defic Syndr. 2014 Jan 21
 Abstract

FULL-TEXT ARTICLE
 Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP).
Liu AY, Yang Q, Huang Y, Bacchetti P,. et al
PLoS One. 2014 Jan 8;9(1):e83736.
Paper

Impact of Tenofovir gel as a PrEP on HIV infection: A mathematical model.
Ashrafur Rahman SM, Vaidya NK, Zou X.
 J Theor Biol. 2013 Dec 28.
 Abstract

FULL-TEXT ARTICLE
 Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis.
Chaowanachan T, Krogstad E, Ball C, Woodrow KA.
PLoS One. 2013 Apr 22;8(4):e61416
 Paper

Acceptability of PrEP for HIV Prevention Among Women at High Risk for HIV.
 Guest G, Shattuck D, Johnson L,  et  al
J Womens Health (Larchmt). 2010 Mar 8.
Abstract

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
 Celum C, Baeten JM.
Curr Opin Infect Dis. 2012 Feb;25(1):51-7.
 Abstract

FULL-TEXT ARTICLE
 Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco.
 Liu AY, Vittinghoff E, Sellmeyer DE, et al
PLoS One. 2011;6(8):e23688.
Paper

Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
Alukda D, Sturgis T, Youan BB.
 J Pharm Sci. 2011 Mar 15
Abstract

Co-enrollment in multiple HIV prevention trials - Experiences from the CAPRISA 004 Tenofovir gel trial.
Karim QA, Kharsany AB, Naidoo K,  et al
Contemp Clin Trials. 2011 Jan 25.
 Abstract

Acceptability of PrEP for HIV Prevention Among Women at High Risk for HIV.
 Guest G, Shattuck D, Johnson L,  et al 
J Womens Health (Larchmt). 2010 Mar 8.
Abstract

Changes in sexual risk behavior among participants in a PrEP HIV prevention trial.
Guest G, Shattuck D, Johnson L, et al S
Sex Transm Dis. 2008 Dec;35(12):1002-8
 Abstract

FULL TEXT ARTICLE
 Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind,Randomized, Placebo-Controlled Trial.
Peterson L, Taylor D, Roddy R, et al
PLoS Clin Trials. 2007 May 25;2(5):e27.
 Paper

Tenofovir trials raise ethical issues.
Mills E.
HIV AIDS Policy Law Rev. 2005 Aug;10(2):31-2.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
Pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals: a meta-analysis
C.I. Okwundu, O. Uthman
 (XIX International AIDS Conference)
 Abstract

The role of community engagement in FEM-PrEP
S. Kirkendale, M. Ratlhagana, P. Omullo,  et al
(XIX  International AIDS Conference)
Abstract
Tenofovir/Emtricitabine
     

     Journal Papers, Abstracts, and Commentaries 

 
Tenofovir disoproxil fumarate/emtricitabine fits for all as appropriate HIV-1 preexposure prophylaxis?
 Taramasso L, Riccardi N, Del Puente F, et al
AIDS Res Hum Retroviruses. 2017 Nov 22
 Abstract

InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
 Wang X, Nwokolo N, Korologou-Linden R, et al
HIV Med. 2017 Jun 28.
Abstract

FULL-TEXT ARTICLE
 Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE
Vaccher S, Grulich A, McAllister J, et al
BMJ Open. 2016 Jun 20;6(6):e012179. 
Paper

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
 [No authors listed] 
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):e82
 Abstract

Risks and benefits of HIV pre exposure prophylaxis with tenofovir/emtricitabine in an older man with co-morbidities.
Girometti N, Jones R, Levy J, et al   
AIDS. 2016 May 21
Abstract

Low risk of Proximal Tubular Dysfunction Associated with Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis in Men and Women.
 Mugwanya K, Baeten J, Celum C,  et al  
J Infect Dis. 2016 Mar 29
 Abstract

How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".
 Calabrese SK, Underhill K.
Am J Public Health. 2015 Aug 13:
 Abstract
'The Science of Being a Study Participant: FEM-PrEP Participants' Explanations for Overreporting Adherence to the Study Pills and for the Whereabouts of Unused Pills.
Corneli AL, McKenna K, Perry B, et al.
 J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-584.
 Abstract

Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis.
Lehman DA, Baeten JM, McCoy CO,  et al  
J Infect Dis. 2015 Jan 13. pii: jiu677.
 Abstract

Changes in Glomerular Kidney Function Among HIV-1-Uninfected Men and Women Receiving Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis: A Randomized Clinical Trial.
Mugwanya KK, Wyatt C, Celum C,  at al
JAMA Intern Med. 2014 Dec 22
 Abstract

Dose-response for Starting and Stopping HIV Pre-Exposure Prophylaxis (PrEP) for MSM.
Seifert SM, Glidden DV, Meditz AL,  et al
Clin Infect Dis. 2014 Nov 18.
Abstract

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM, Donnell D, Mugo NR, et al
Lancet Infect Dis. 2014 Oct 8
 Abstract

Daily Oral Tenofovir and Emtricitabine-Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1-Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial.
Celum C, Morrow RA, Donnell D,  et al
Ann Intern Med. 2014 Jul 1;161(1):11-19.
 Abstract

HIV-1 Drug Resistance in the iPrEx Pre-Exposure Prophylaxis Trial.
 Liegler T, Abdel-Mohsen M, Bentley LG,  et al
 J Infect Dis. 2014 Apr 16. 
Abstract
FULL-TEXT ARTICLE
 No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis.
Marcus JL, Glidden DV, Mayer KH,  et al
PLoS One. 2013 Dec 18;8(12):e81997.
Paper

Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine.
Boot J, Rump BO, Boucher CA, et al
Ned Tijdschr Geneeskd. 2013;157(27):A6063
 Abstract

Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis.
 Plosker GL.
Drugs. 2013 Feb 27
 Abstract

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men.
Anderson PL, Glidden DV, Liu A et al.
Sci Transl Med. 2012 Sep 12;4(151):
 Abstract

Oral antiretroviral chemoprophylaxis: current status.
Baeten J, Celum C.
 Curr Opin HIV AIDS. 2012 Sep 7
 Abstract

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.
Baeten JM, Donnell D, Ndase P, Mugo NR,  et al
N Engl J Med. 2012 Jul 11. .
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
 

Enrollment into open-label phase of TDF2 PrEP Study, Botswana, 2013
L. Chirwa, A. Taylor, T. Williams, et al
 (XX International AIDS Conference)
 Abstract

Acceptability of HIV pre-exposure prophylaxis (PrEP) with Truvada among men who have sex with men (MSM) and male-to-female transgender persons (TG) in northern Thailand
D. Yang C. Chariyalertsak, A. Wongthanee, et  al
(XIX International AIDS Conference)
 Abstract

Switching from abacavir/lamivudine to tenofovirDF/emtricitabine reduces biomarkers of inflammation
O. Alozie, R. Prosser, K. Huppler Hullsiek, et al
 (XIX International AIDS Conference)
 Abstract
 
Delayed emergence of HIV-1 variants resistant to 4'-ethnyl-2-fluoro-2'-deoxyadenosine (EFdA): comparative sequential passage study with tenofovir, emtricitabine and festinavir
K. Maeda, D. Desai, H. Nakata,, H. Mitsuya
 (XIX International AIDS Conference)
 Abstract

     Videos

 
  • Stopping HIV? The Truvada Revolution (Full Length)
Cabotegravir (GSK1265744)
     

 Journal Papers, Abstracts, and Commentaries 
 

  Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection.
 Taha H, Morgan J, Das A, Das S.
Recent Pat Antiinfect Drug Discov. 2013 Dec;8(3):213-8.
Abstract

 

HIV PreP Main Page Main New/Newsworthy Home Page

HIV Infection/Disease:
Pre-Exposure Prophylaxis Drugs